Wiener klinische Wochenschrift

, Volume 124, Issue 3–4, pp 104–110 | Cite as

Austrian Joint ÖGGH-ÖGIR-ÖGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma

  • Markus Peck-Radosavljevic
  • Wolfgang Sieghart
  • Claus Kölblinger
  • Markus Reiter
  • Martin Schindl
  • Gregor Ulbrich
  • Rudolf Steininger
  • Christian Müller
  • Rudolf Stauber
  • Maximilian Schöniger-Hekele
  • Manfred Gschwendtner
  • Christina Plank
  • Martin Funovics
  • Ivo Graziadei
  • Johannes Lammer
  • Thomas Gruenberger
  • Günther Gastl
  • Franz Karnel
  • the Austrian Association of Gastroenterology,Hepatology (ÖGGH)
  • the Austrian Society of Interventional Radiology (ÖGIR)
  • the Austrian Society of Hematology and Oncology (ÖGHO)
  • the Austrian Society for Surgical Oncology (ASSO)
Consensus report

Summary

Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) is one of the most frequently applied standard treatments for this disease. The role for TACE is fairly well defined within the most widely used treatment algorithm for HCC, die Barcelona Clinic Liver Cancer (BCLC) staging system and treatment algorithm. But no general treatment algorithm will go into the technical details of any procedure and several patients will not fit ideally into the patient groups predefined in BCLC or any other treatment algorithm. Furthermore, indications and contraindications sometimes are viewed differently by the various medical specialties involved in taking care of such patients. We present here the joint expert position statement of the Austrian Societies of Gastroenterology and Hepatology (ÖGGH), Interventional Radiology (ÖGIR), Hematology and Oncology (ÖGHO), and Surgical Oncology (ASSO) on the technical aspects, indications, and contraindication for the use of TACE in the management of HCC.

Keywords

Hepatocellular carcinoma TACE Transarterial chemoembolization BCLC Drug-eluting beads 

Gemeinsames österreichisches ÖGGH-ÖGIR-ÖGHO-ASSO Positionspapier zum Einsatz der transarteriellen Chemoembolisation (TACE) beim Hepatozellulären Karzinom

Zusammenfassung

Die transarterielle Chemoembolisation (TACE) bei hepatozellulärem Karzinom (HCC) ist eine der meistverwendeten Standardtechniken zur Behandlung dieser Erkrankung. Die Rolle der TACE ist relativ gut definiert für den am meisten verwendeten Behandlungsalgorithmus, den "Barcelona Clinic Liver Cancer (BCLC) Staging System and Treatment" Algorithmus. Aber kein allgemeiner Behandlungsalgorithmus geht auf die technischen Details des Eingriffs ein und zudem gibt es immer einige Patienten, welche nicht genau in die von BCLC oder einem anderen Behandlungsschema vordefinierten Gruppen passen. Ausserdem werden Indikationen und Kontraindikationen manchmal von den unterschiedlichen Fachdisziplinen, welche in das Management dieser Patienten involviert sind, unterschiedlich gesehen. Wir präsentieren hier das gemeinsame Experten-Positionspapier der Österreichischen Gesellschaften für Gastroenterologie und Hepatologie (ÖGGH), Interventionelle Radiologie (ÖGIR), Hämatologie und Onkologie (ÖGHO) und Chirurgische Onkologie (ASSO) bezüglich der technischen Aspekte, der Indikationen und der Kontraindikationen für den Einsatz der TACE im Management des HCC.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762–73PubMedCrossRefGoogle Scholar
  2. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011;53:1020–2PubMedCrossRefGoogle Scholar
  3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–17PubMedCrossRefGoogle Scholar
  4. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, et al. Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. Gastroenterology 2010;138:52PubMedCrossRefGoogle Scholar
  5. Jelic S, Sotiropoulos GC. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v59–64PubMedCrossRefGoogle Scholar
  6. Brown DB, Cardella JF, Sacks D, Goldberg SN, Gervais DA, Rajan DK, Vedantham S, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2009;20:S219–S226, S226 e211–210PubMedCrossRefGoogle Scholar
  7. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011;37:212–20PubMedCrossRefGoogle Scholar
  8. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164–71PubMedCrossRefGoogle Scholar
  9. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734–9PubMedCrossRefGoogle Scholar
  10. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6–25PubMedCrossRefGoogle Scholar
  11. Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, Makuuchi M. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol 2010;194:830–7PubMedCrossRefGoogle Scholar
  12. Kwok PC, Lam TW, Chan SC, Chung CP, Wong WK, Chan MK, Lo HY, et al. A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. J Hepatol 2000;32:955–64PubMedCrossRefGoogle Scholar
  13. Brown DB, Pilgram TK, Darcy MD, Fundakowski CE, Lisker-Melman M, Chapman WC, Crippin JS. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 2005;16:1661–6PubMedCrossRefGoogle Scholar
  14. Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 2009;10:425–34PubMedCrossRefGoogle Scholar
  15. Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170:783–6PubMedGoogle Scholar
  16. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006;12:2563–7PubMedCrossRefGoogle Scholar
  17. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474–81PubMedCrossRefGoogle Scholar
  18. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41–52PubMedCrossRefGoogle Scholar
  19. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010;101:476–80PubMedGoogle Scholar
  20. Covey AM, Maluccio MA, Brody LA, Sofocleous CT, Getrajdman GI, Brown KT. Re: Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 2006;17:1209; author reply 1209–10PubMedCrossRefGoogle Scholar
  21. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, Moschouris H, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;33:541–51PubMedCrossRefGoogle Scholar
  22. Malagari K, Pomoni M, Spyridopoulos TN, Moschouris H, Kelekis A, Dourakis S, Alexopoulou E, et al. Safety Profile of Sequential Transcatheter Chemoembolization with DC Bead(): Results of 237 Hepatocellular Carcinoma (HCC) Patients. Cardiovasc Intervent Radiol 2010Google Scholar
  23. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, Hasegawa H, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987;163:345–51PubMedGoogle Scholar
  24. Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Sugimori N, Igarashi S, Nakashima Y, et al. Usefulness of cone-beam computed tomography during ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinomas that cannot be demonstrated on angiography. Cardiovasc Intervent Radiol 2009;32:255–64PubMedCrossRefGoogle Scholar
  25. Takayasu K. Chemoembolization for unresectable hepatocellular carcinoma in Japan. Oncology 2010;78 Suppl 1:135–41PubMedCrossRefGoogle Scholar
  26. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011;3:CD004787PubMedGoogle Scholar
  27. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429–42PubMedCrossRefGoogle Scholar
  28. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, Lau WY, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 2009;249:195–202PubMedCrossRefGoogle Scholar
  29. Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, Visa J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996;111:1018–22PubMedCrossRefGoogle Scholar
  30. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis [see comments]. N Engl J Med 1996;334:693–9PubMedCrossRefGoogle Scholar
  31. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90PubMedCrossRefGoogle Scholar
  32. Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 2009;20:S317–23PubMedCrossRefGoogle Scholar
  33. Lencioni R, Llovet JM. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. Semin Liver Dis 2010;30:52–60PubMedCrossRefGoogle Scholar
  34. Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z, Kickuth R, et al. Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study. Oncologist 2010Google Scholar
  35. Pinter M, Sieghart W, Reiberger T, Ferlitsch A, Müller C, Peck-Radosavljevic M. An interim safety analysis of sorafenib plus transarterial chemoembolization in hepatocellular carcinoma – a phase I/II pilot study (SORATCAE-1 trial). Hepatology 2010;52 (Suppl. 1):A1759Google Scholar
  36. Ulbrich G, Kölblinger C, Pinter M, Reiberger T, Ferlitsch A, Sieghart W, Lammer J, et al. AVATACE-1 trial: Bevacizumab as inhibitor of collateral tumor-vessel-growth during transarterial chemoembolisation (TACE) for Hepatocellular Carcinoma - a double-blind, randomized, placebo-controlled pilot-trial. Hepatology 2010;52 (Suppl. 1):A1763Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Markus Peck-Radosavljevic
    • 1
  • Wolfgang Sieghart
    • 1
  • Claus Kölblinger
    • 2
  • Markus Reiter
    • 3
  • Martin Schindl
    • 4
  • Gregor Ulbrich
    • 5
  • Rudolf Steininger
    • 4
  • Christian Müller
    • 1
  • Rudolf Stauber
    • 6
  • Maximilian Schöniger-Hekele
    • 1
  • Manfred Gschwendtner
    • 7
  • Christina Plank
    • 2
  • Martin Funovics
    • 2
  • Ivo Graziadei
    • 8
  • Johannes Lammer
    • 2
  • Thomas Gruenberger
    • 9
  • Günther Gastl
    • 10
  • Franz Karnel
    • 11
  • the Austrian Association of Gastroenterology,Hepatology (ÖGGH)
  • the Austrian Society of Interventional Radiology (ÖGIR)
  • the Austrian Society of Hematology and Oncology (ÖGHO)
  • the Austrian Society for Surgical Oncology (ASSO)
  1. 1.Abteilung Gastroenterologie & Hepatologie, KIM IIIAKH & MedUniWienViennaAustria
  2. 2.Abteilung Kardiovaskuläre und Interventionelle Radiologie, Klinik für RadiodiagnostikAKH & MedUniWienViennaAustria
  3. 3.ZentralröntgenKA RudolfstiftungViennaAustria
  4. 4.Abteilung für TransplantationUniversitätsklinik für Chirurgie, AKH & MedUniWienViennaAustria
  5. 5.1. Medizinische Abteilung mit GastroenterologieKrankenhaus HitzingViennaAustria
  6. 6.Klinische Abteilung für Gastroenterologie und HepatologieMedizinische Universität GrazGrazAustria
  7. 7.Institut für diagnostische und interventionelle RadiologieKrankenhaus der Elisabethinen LinzLinzAustria
  8. 8.Klinische Abteilung für Gastroenterologie und HepatologieMedizinische Universität InnsbruckInnsbruckAustria
  9. 9.Abteilung für AllgemeinchirurgieUniversitätsklinik für Chirurgie, AKH & MedUniWienViennaAustria
  10. 10.Universitätsklinik für Innere Medizin V, Hämatologie und OnkologieMedizinische Universität InnsbruckInnsbruckAustria
  11. 11.Zentralröntgen, SMZ-SüdKaiser Franz Josef SpitalViennaAustria

Personalised recommendations